The battle between drugs giants Boehringer Ingelheim, Glaxo and Eli Lilly against parallel importers Dowelhurt and Swingward has been fought out keenly in the UK courts, having been referred to the European Court of Justice some years ago for a reference as to the extent to which the relabelling, over-stickering and repackaging of trade mark-protected pharma products was justifiable as being objectively necessary. Perhaps not surprisingly, this huge case is in the news again. The Court of Appeal for England and Wales has just sent the case back to Brussels for a further reference.
The IPKat will tell you what it's all about once he's had the chance to read it and ponder, so watch this space.
Home »
» PHARMA REPACKAGING BATTLE GOES BACK TO LUXEMBOURG